Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recent advances in the discovery of potent RNA-dependent RNA-polymerase (RdRp) inhibitors targeting viruses

23 Dec 2020

Abstract excerpt

) computational approach. From the beginning, viral replication has been the main focus for any antiviral drug development for viral diseases, including HCV, influenza virus, zika virus, norovirus, measles, dengue virus, and coronaviruses. This review lists the nucleoside, nucleotide, and non-nucleoside RdRp inhibitor analogues of various viral diseases that may be evaluated for drug development to treat COVID-19.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology
Share to Viral Infections and Immunology Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34046618
DOI: 10.1039/d0md00318b

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recent advances in the discovery of potent RNA-dependent RNA-polymerase (RdRp) inhibitors targeting virusesPMID 34046618Read ↗

An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challengesSemantic proximity Read ↗

Recent advancements in the discovery of small-molecule non-nucleoside inhibitors targeting SARS-CoV-2 RdRpSemantic proximity Read ↗

Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design ChallengeSemantic proximity Read ↗

Nucleotide and nucleoside-based drugs: past, present, and futureSemantic proximity Read ↗

RdRp inhibitors and COVID-19: Is molnupiravir a good option?Semantic proximity Read ↗

Identification of a Broad-Spectrum Viral Inhibitor Targeting a Novel Allosteric Site in the RNA-Dependent RNA Polymerases of Dengue Virus and NorovirusSemantic proximity Read ↗

In silico analysis of RNA-dependent RNA polymerase of the SARS-CoV-2 and potentiality of the pre-existing drugsSemantic proximity Read ↗

Insights into RNA-dependent RNA Polymerase Inhibitors as Antiinfluenza Virus AgentsSemantic proximity Read ↗

Inhibition of Viral RNA-Dependent RNA Polymerases by Nucleoside Inhibitors: An Illustration of the Unity and Diversity of MechanismsSemantic proximity Read ↗

A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitroSemantic proximity Read ↗

New perspective of small-molecule antiviral drugs development for RNA virusesSemantic proximity Read ↗

Small Molecule Drugs Targeting Viral PolymerasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.